BioSpace News Archive

The global biopharmaceuticals market size was exhibited at USD 333.09 billion in 2022 and is expected to hold around USD 856.1 billion by 2030, growing at a CAGR of 12.5% from 2022 to 2030.

The global pharmacovigilance market size was exhibited at USD 9.07 billion in 2022 and it is expected to hold around USD 16.23 billion by 2030, growing at a CAGR of 7.5% from 2022 to 2030.

Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) is pleased to announce a positive recommendation from the Institut national d’excellence en santé et en services sociaux (INESSS) for RADICAVA® Oral Suspension, the oral formulation of RADICAVA® IV (edaravone), for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS).

Empirical Spine, Inc., a medical device company creating a new class of spinal implant, recently completed the final step in the U.S. Food & Drug Administration (FDA) submission process for the LimiFlex™ Dynamic Sagittal Tether™ (DST).

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) announced today that Health Canada has approved for use in Canada the Quidel TriageTrue High-Sensitivity Troponin I (hsTnl) Test on the Quidel Triage® MeterPro®, a high-performance, comprehensive testing platform with the smallest footprint analyzer, to aid in the diagnosis of myocardial infarction.

A Sudan ebolavirus vaccine and antibody therapeutic tested at Texas Biomedical Research Institute have been sent to Uganda as part of efforts to control the outbreak there.

Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three new employees to purchase an aggregate of 42,500 ordinary shares under Avadel’s 2021 Inducement Plan.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the addition of five senior executives to help further strengthen the company’s product roadmap and improve commercial execution.

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it will report top-line Phase 3 data from its ENHANCE-1 trial of nebulized ensifentrine on Tuesday, December 20, 2022.

Precigen, Inc. (Nasdaq: PGEN) today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 3:45 PM PT/6:45 PM ET in San Francisco, California.